Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases

Arthritis and Rheumatism

Volumn 58, Issue 2, 2008, Pages 521-531

  Jais, Xavier ^a   Launay, David ^a,b   Yaici, Azzedine ^a   Le Pavec, Jérôme ^a   Tchérakian, Colas ^a   Sitbon, Olivier ^a   Simonneau, Gérald ^a   Humbert, Marc ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CYCLOPHOSPHAMIDE; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXYGEN; PREDNISONE; PROSTACYCLIN; SILDENAFIL; UNIPROST; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DRUG DOSE REDUCTION; DRUG FATALITY; FEMALE; HEART INDEX; HEMODYNAMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKONEUTROPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUPUS ERYTHEMATOSUS; MALE; MIXED CONNECTIVE TISSUE DISEASE; NAUSEA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WALKING;

ADULT; ALGORITHMS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; PREDICTIVE VALUE OF TESTS; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 39749156384     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23303     Document Type: Article

References (34)

1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5-12S.
2. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.
3. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilla J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
4. Tanoue LT. Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med 2003;24:287-96.
5. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-63.
6. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13-24S.
7. Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007;38:893-902.
8. Tuder RM, Groves B, Badesh DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-85.
9. Yeo PP, Sinniah R. Lupus cor pulmonale with electron microscope and immunofluorescent antibody studies. Ann Rheum Dis 1975;34:457-60.
10. Brentjens J, Ossi E, Albini B, Sepulveda M, Kano K, Sheffer J, et al. Disseminated immune deposits in lupus erythematosus. Arthritis Rheum 1977;20:962-8.
11. 3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1419-25.
12. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554-9.
13. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002;29:282-7.
14. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990;17:1292-8.
15. Sato M, Okazaki H, Okamoto H, Ohtaka A, Shimizu H, Minato N, et al. Pulmonary hypertension in systemic lupus erythematosus: a report of an autopsied case. Intern Med 1994;33:540-2.
16. Groen H, Bootsma H, Postma DS, Kallenberg CG. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 1993;20:1055-7.
17. Karmochkine M, Wechsler B, Godeau P, Brenot F, Jagot JL, Simonneau G. Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis 1996;55:561-2.
18. Kawaguchi Y, Hara M, Harigai M, Sakurada M, Nakamura H, Kashiwazaki S. Corticosteroid pulse therapy in a patient with SLE and pulmonary hypertension. Clin Exp Rheumatol 1998;16:510.
19. Galie N, Manes A, Farahani KV, Pelino F, Palazzini M, Negro L, et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005;14:713-7.
20. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006;130:182-9.
21. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
22. Alarcon-Segovia D, Cardiel M. Comparison between 3 diagnostic criteria for mixed connective tissue disease. J Rheumatol 1989;16:328-34.
23. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
24. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
25. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
26. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999;54:273-7.
27. Perez HD, Kramer N. Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 1981;11:177-81.
28. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005;14 Suppl:s33-8.
29. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589-95.
30. Kawamura N, Tsutsui H, Fukuyama K, Hayashidani S, Koike G, Egashira K, et al. Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity. Intern Med 2002;41:109-12.
31. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000;117:14-8.
32. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31.
33. Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al, and the French Vasculitis Study Group. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
34. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.